Meeting
2017 ASCO Annual Meeting
Standard anthracycline-based vs. docetaxel-capecitabine in early breast cancer: Results from the chemotherapy randomization (R-C) of EORTC 10041/ BIG 3-04 MINDACT phase III trial.
Authors
Fatima Cardoso
Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal
Fatima Cardoso , Martine J. Piccart-Gebhart , Emiel J. Rutgers , Saskia Litière , Laura Van't Veer , Giuseppe Viale , Jean-Yves Pierga , Franchette W.P.J. van den Berkmortel , Etienne Brain , Patricia Gomez , Theodora Goulioti , Susan Knox , Elisabeth Luporsi , Ulrike Nitz , Isabel T Rubio , Lisette Stork , Peter Vuylsteke , KONSTANTINOS TRYFONIDIS , Jan Bogaerts , Suzette Delaloge
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00433589
Citation
J Clin Oncol 35, 2017 (suppl; abstr 516)
DOI
10.1200/JCO.2017.35.15_suppl.516
Abstract #
516
Poster Bd #
116
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Final analysis of the PROMISE-GIM6 phase III trial assessing GnRH agonist use during chemotherapy as a strategy to preserve ovarian function in premenopausal patients with early breast cancer.
First Author: Matteo Lambertini
First Author: Begoña Bermejo
Poster
2023 ASCO Annual Meeting
Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial.
First Author: Sylvie Giacchetti
Poster
2023 ASCO Annual Meeting
Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2− early breast cancer (EBC): A correlation analysis.
First Author: Michael Untch